{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:04:38Z","timestamp":1756339478953,"version":"3.44.0"},"reference-count":15,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2014,8,31]]},"abstract":"<jats:p>Cannabis is one of the most commonly used recreational drugs worldwide. Psychoactive properties of the principal compound, \u03b4-9-tetrahydrocannabinol include euphoria, a sense of relaxation and increased appetite. Chronic cannabis use has been associated with the development of a withdrawal syndrome on abrupt discontinuation. Withdrawal symptoms typically begin within 24\u2005h of abstinence and manifest as irritability, nervousness, sleep disturbances and decreased appetite. There is growing evidence that supports the use of plant-derived and synthetic cannabinoids for the treatment of cannabis withdrawal. In this case report, we present 20-year-old woman who developed protracted nausea and vomiting secondary to cannabis withdrawal and was successfully treated with nabilone. Nausea and vomiting is not listed in the Diagnostic and Statistical Manual-5 diagnostic criteria for cannabis withdrawal syndrome and is an uncommon symptom presentation.<\/jats:p>","DOI":"10.1136\/bcr-2014-205287","type":"journal-article","created":{"date-parts":[[2014,9,22]],"date-time":"2014-09-22T07:03:00Z","timestamp":1411369380000},"page":"bcr2014205287","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Nabilone therapy for cannabis withdrawal presenting as protracted nausea and vomiting"],"prefix":"10.1136","volume":"2014","author":[{"given":"Philip W","family":"Lam","sequence":"first","affiliation":[{"name":"Division of General Internal Medicine, University Health Network, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W","family":"Frost","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, University Health Network, Toronto, Canada"},{"name":"Department of Medicine, University of Toronto, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2014,9,22]]},"reference":[{"key":"2025082707334103000_2014.sep22_1.bcr2014205287.1","unstructured":"Health Canada. Canadian Alcohol and Drug Use Monitoring Survey. 2011. http:\/\/www.hc-sc.gc.ca\/hc-ps\/drugs-drogues\/stat\/_2011\/summary-sommaire-eng.php (accessed 1 Apr 2014)."},{"key":"2025082707334103000_2014.sep22_1.bcr2014205287.2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-258"},{"key":"2025082707334103000_2014.sep22_1.bcr2014205287.3","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1999.94913114.x"},{"key":"2025082707334103000_2014.sep22_1.bcr2014205287.4","doi-asserted-by":"publisher","DOI":"10.2174\/138161211796150846"},{"key":"2025082707334103000_2014.sep22_1.bcr2014205287.5","doi-asserted-by":"publisher","DOI":"10.2174\/1874473711104040241"},{"key":"2025082707334103000_2014.sep22_1.bcr2014205287.6","doi-asserted-by":"publisher","DOI":"10.1126\/science.276.5321.2048"},{"key":"2025082707334103000_2014.sep22_1.bcr2014205287.7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300310"},{"key":"2025082707334103000_2014.sep22_1.bcr2014205287.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2006.04.014"},{"key":"2025082707334103000_2014.sep22_1.bcr2014205287.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2010.12.010"},{"key":"2025082707334103000_2014.sep22_1.bcr2014205287.10","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2013.54"},{"key":"2025082707334103000_2014.sep22_1.bcr2014205287.11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/17523281.2012.693520","article-title":"A double-blind placebo control pilot study on the safety and tolerability of Nabilone in marijuana users","volume":"6","author":"Lu","year":"2012","journal-title":"Ment Health Subst Use"},{"key":"2025082707334103000_2014.sep22_1.bcr2014205287.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1369-1600.2011.00427.x"},{"key":"2025082707334103000_2014.sep22_1.bcr2014205287.13","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edn. Arlington, VA: American Psychiatric Association, 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"2025082707334103000_2014.sep22_1.bcr2014205287.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2010.04.010"},{"key":"2025082707334103000_2014.sep22_1.bcr2014205287.15","doi-asserted-by":"publisher","DOI":"10.1002\/eat.22229"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2014-205287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T14:33:50Z","timestamp":1756305230000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2014-205287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,22]]},"references-count":15,"alternative-id":["10.1136\/bcr-2014-205287"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2014-205287","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2014,9,22]]}}}